ARWR — ARROWHEAD PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 879407 ·
Last close
$65.92
Market Cap
$9.31B
52W High
$95.49
52W Low
$31.45
ADV30
1,820,937
Next earnings
2026-11-24
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 75,253,000 | — | -170,093,000 | -194,280,000 | 2,112,013,000 | 19,685,000 | 1,645,972,000 |
| Mar 2026 | 73,737,000 | — | -141,260,000 | -132,732,000 | 2,268,265,000 | 147,531,000 | 1,669,349,000 |
| Dec 2025 | 264,033,000 | — | 40,809,000 | 30,811,000 | 1,604,181,000 | 71,370,000 | 1,041,484,000 |
| Sep 2025 | 256,472,000 | — | 44,106,000 | -23,750,000 | 1,385,295,000 | 88,706,000 | 881,879,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-36,306,000
Investing CF
$-704,015,000
Financing CF
$741,957,000
CapEx
$-14,566,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.78
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,923,355,000
Inventory
—
Receivables
$8,556,000
ST Investments
$1,582,275,000
EBIT TTM
$-159,471,000
Pretax Income TTM
$-252,078,000
Interest Exp TTM
$92,607,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$669,494,976
EBITDA
$-200,635,008
Free Cash Flow
$-48,628,124
Enterprise Value
$11,484,989,440
Total Cash
$1,597,859,968
Total Debt
$1,379,405,056
Shares Out
141,254,467
Trailing EPS
$-2.28
Book Value
$3.30
ROE
-55.2%
ROA
-8.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 829,448,000 | 98,346,000 | -1,631,000 | 1,385,295,000 | 881,879,000 | 466,052,000 | 179,552,000 |
| Sep 2024 | 3,551,000 | -601,080,000 | -599,493,000 | 1,139,802,000 | 948,739,000 | 185,444,000 | -462,851,000 |
| Sep 2023 | 240,735,000 | -205,002,000 | -205,275,000 | 765,552,000 | 478,390,000 | 271,343,000 | -153,890,000 |
| Sep 2022 | 243,231,000 | -178,507,000 | -176,063,000 | 691,939,000 | 273,600,000 | 398,520,000 | -136,131,000 |
TTM Snapshot
Revenues TTM
$542,709,000
NetIncome TTM
$370,445,000
OpCashFlow TTM
$0
Assets (Latest)
$1,385,295,000
Forward EPS
$-4.80
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $82.50 · spot: $65.92 · call volume: 639 · put volume: 287
Expected Move to 2026-10-16:
±$6.30
(9.56%) —
implied range
$59.62 –
$72.22
· ATM straddle on $65.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PTGX | Protagonist Therapeutics, Inc | $9.18B | $141.86 | — |
| CYTK | CYTOKINETICS INC | $8.99B | $64.66 | — |
| TGTX | TG THERAPEUTICS, INC. | $8.79B | $57.43 | — |
| RDY | DR REDDYS LABORATORIES LTD | $10.20B | $12.25 | — |
| AXSM | Axsome Therapeutics, Inc. | $10.22B | $195.09 | — |
News headlines (Yahoo Finance, 1h cache)
ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near
2026-09-24 11:20 · Yahoo
Arrowhead Pharmaceuticals (ARWR) On ARO DIMER PA Data And Whether Undervaluation Still Holds
2026-09-19 04:18 · Yahoo
Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress
2026-09-19 00:02 · Yahoo
Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands
2026-09-18 21:02 · Yahoo
RNA Interference Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Silence Therapeutics
2026-09-18 10:42 · Yahoo
Not A ‘Gangbusters Launch’ — Arrowhead Predicts Slow Burn to $3B-$4B Peak For Redemplo, Highlights ‘Massive Pipeline’
2026-09-16 17:41 · Yahoo
Arrowhead Achieves Clinical Validation for New Drug Platform
2026-09-16 11:39 · Yahoo
ARWR Stock Heads For Worst Day In Over A Year Despite Positive Cholesterol Drug Data — Is This A ‘Sell The News’ Move?
2026-09-15 19:03 · Yahoo
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
2026-09-15 11:30 · Yahoo
ARWR: SHASTA-3 and SHASTA-4 Data Presented at ESC 2026
2026-09-08 11:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.